ArticleJournal, genetic engineering & biotechnology2025

Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.

Peter Jerome Ishmael V Paulino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.